A Randomized, Placebo-Controlled, Sequential, Multiple-Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MAR701/RO6807952 in Type 2 Diabetic Patients.
Phase of Trial: Phase I
Latest Information Update: 11 Jun 2016
At a glance
- Drugs RG 7685 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Roche
- 10 Jun 2017 Biomarkers information updated
- 20 Jan 2014 Actual end date changed from 1 Mar 2012 to 1 Sep 2011 as reported by ClinicalTrials.gov record.
- 20 Dec 2012 Status changed from active, no longer recruiting to completed.